Tempus AI, Inc. (TEM)
Tempus: Is This Ultra-Fast-Growing Company A Good Investment?
Tempus AI, Inc. is growing rapidly in healthcare tech, especially genomics, but is not yet profitable and carries significant risk. Recent revenue growth is boosted by the Ambry Genetics acquisition; organic growth remains strong, but future growth may slow post-acquisition. The company benefits from exposure to large, expanding markets and leverages AI/data partnerships, but faces high valuation multiples.
After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order?
President Donald Trump's new executive order aiming to cut U.S. drug prices could benefit Tempus AI.
Tempus AI, Inc. (TEM) Q1 2025 Earnings Call Transcript
Tempus AI, Inc. (NASDAQ:TEM ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Liz Krutoholow – Vice President-Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer Jim Rogers – Chief Financial Officer Conference Call Participants Tejas Savant – Morgan Stanley Ryan MacDonald – Needham & Company Mark Schappel – Loop Capital Subbu Nambi – Guggenheim Daniel Brennan – TD Cowen Mark Massaro – BTIG Michael Ryskin – Bank of America Rachel Vatnsdal – JPMorgan Dan Arias – Stifel Operator Good day everyone. And thank you for standing by.
TEMPUS (Nasdaq: TEM) Earnings: Live Coverage And What to Expect
Tempus AI (NASDAQ: TEM), a fast-rising player in clinical AI and health data infrastructure, will report its Q1 2025 earnings after the market closes today.
Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings?
TEM's Genomics unit is expected to report strong growth for the first quarter, banking on continued unit growth pick-up.
Why Tempus AI Stock Is Skyrocketing Today
Shares of Tempus AI (TEM 17.39%) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday.
Tempus AI: Cooldown Arrived (Rating Upgrade)
Tempus AI is trading near yearly lows despite strong growth prospects, driven by the Ambry Genetics acquisition and robust organic growth. The company has innovative AI diagnostic services, including new cancer tests and CMS-approved algorithms, positioning it for continued 25% annual growth. TEM stock has a market cap of ~$7 billion and trades at 4.5x sales, offering compelling value and growth potential for investors.
Thermo Fisher Stock Benefits From the Launch of Krios 5 Cryo-TEM
TMO launches the Krios 5 Cryo-TEM, boosting productivity and performance with enhanced automation.
Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock?
The February 2025 acquisition of Ambry Genetics further expands TEM's genomics capabilities with a West Coast lab and enhanced inherited risk testing.
Tempus AI: The Investment Opportunity Of A Decade, Strong Buy
Tempus AI's financials have significantly improved, with positive cash flow expected next quarter and strong revenue growth projected for FY25. Q4FY24 saw record revenues, driven by a 35.8% YoY growth, with the Data & Services segment growing by 44.6% YoY. FY24 revenues hit an all-time high of $693.4 million, with major agreements signed and the launch of the AI-enabled health app, Olivia.
Tempus AI Surges 40% YTD: Are New Strategic Deals a Buy Signal?
The market's appetite for AI applications in healthcare is rapidly increasing, with TEM emerging as a top contender in this high-growth sector.
Tempus Stock May Rise on the Acquisition of AI-Driven Deep 6 AI
TEM announces the acquisition of Deep 6 AI, enhancing its AI-driven clinical trial matching capabilities to accelerate patient recruitment and revolutionize precision medicine.
